ALFU-KAL XL

Šalis: Izraelis

kalba: anglų

Šaltinis: Ministry of Health

Veiklioji medžiaga:

ALFUZOSIN HYDROCHLORIDE

Prieinama:

PADAGIS ISRAEL AGENCIES LTD, ISRAEL

ATC kodas:

G04CA01

Vaisto forma:

TABLETS PROLONGED RELEASE

Sudėtis:

ALFUZOSIN HYDROCHLORIDE 10 MG

Vartojimo būdas:

PER OS

Recepto tipas:

Required

Pagaminta:

RIVOPHARM SA, SWITZERLAND

Farmakoterapinė grupė:

ALFUZOSIN

Gydymo sritis:

ALFUZOSIN

Terapinės indikacijos:

Treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. Adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.

Leidimo data:

2014-07-31

Pakuotės lapelis

PATIENT PACKAGE INSERT IN
ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s
prescription only
ALFU-KAL XL
PROLONGED-RELEASE TABLETS
Each prolonged-release tablet contains:
Alfuzosin Hydrochloride 10 mg.
Inactive ingredients: see section 6 in the
leaflet.
READ THE LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE.
Keep this leaflet; you may need to read
it again. This leaflet contains concise
information about the medicine. If you have
further questions, refer to the doctor or
pharmacist.
This medicine has been prescribed to treat
you. Do not pass it on to others. It may harm
them, even if it seems to you that their medical
condition is similar. The medicine is intended
for men. This medicine is not intended for
treatment of children and adolescents under
16 years of age.
1. WHAT IS THE MEDICINE INTENDED
FOR?
Alfu-Kal XL is used to treat symptoms
associated with benign prostatic hypertrophy
and as an adjuvant treatment to catheter
withdrawal in urinary retention resulting from
benign prostatic hypertrophy.
THERAPEUTIC GROUP: Alfu-Kal XL belongs
to a group of preparations called alpha
blockers and is a selective blocker of the α1
(alpha one) receptor.
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
• You are sensitive )allergic( to the active
ingredient alfuzosin or to any of the
additional ingredients contained in
the medicine (see section 6 “Further
information”).
• You suffer, or have suffered in the past,
from a sudden drop in blood pressure
when you get up from a sitting or
lying position, possibly accompanied
by dizziness or fainting (orthostatic
hypotension).
• You suffer from a liver function problem.
• You are being treated with other
α blockers (e.g., prazosin, trimazosin,
urapidil).
• Children under the age of 16.
SPECIAL WARNINGS REGARDING USE OF THE
MEDICINE
Before starting treatment with the medicine,
tell the doctor if:
• If you show symptoms of orthostatic
hypotension (a sudden drop in blood
pressur